Robbins LLP Urges Semler Scientific Shareholders to Act Before Lead Plaintiff Deadline for Class Action

Robbins LLP Warns Semler Scientific Shareholders of Class Action

Semler Scientific, Inc. (NASDAQ: SMLR) is at the center of a significant class action lawsuit that affects stockholders who purchased or acquired its securities between March 10, 2021, and April 15, 2025. Robbins LLP, a renowned shareholder rights law firm, is actively urging affected investors to reach out to them for crucial information regarding this legal action.

Semler Scientific, which specializes in developing and marketing technology products and services aimed at tackling chronic diseases, has found itself embroiled in serious allegations. The company has been accused of failing to disclose an investigation led by the U.S. Department of Justice pertaining to potential violations of the False Claims Act. During discussions, Semler allegedly presented these investigations in a hypothetical context, misleading shareholders about the gravity of the issue.

According to the complaint details, it was revealed on February 28, 2025, that Semler had received a civil investigative demand from the DOJ back in July 2017. This demand was part of an inquiry into whether the company made inappropriate claims regarding the eligibility of certain tests for Medicare reimbursement, which could contravene applicable laws.

To exacerbate matters, further investigative demands were issued subsequently, and a settlement discussion initiated with the DOJ in February 2025 failed to bring resolution. This unraveling of events reportedly resulted in a significant devaluation of Semler's stock, nosediving by 9.38% immediately following the disclosure.

The situation escalated on April 15, 2025, when Semler announced through a SEC Form 8-K that it had reached a tentative agreement to settle the claim with the DOJ for approximately $29.75 million. However, even with this settlement, the company cautioned stakeholders that there could be further financial implications or litigation risks in the future.

For those who may have invested in Semler Scientific during the said period, there is still time to take action. Robbins LLP emphasizes that shareholders who wish to serve as lead plaintiffs must submit their requests by October 28, 2025. A lead plaintiff plays a pivotal role in guiding the litigation process on behalf of other class members and can contribute to the overall strategy and direction of the legal recourse.

It’s important to note that individuals do not need to actively participate to qualify for a recovery. Shareholders who choose not to engage remain class members and may still be eligible for any financial restitution awarded in the case. Moreover, Robbins LLP works strictly on a contingency fee basis, meaning shareholders incur no costs unless a favorable outcome is secured.

With a history dating back to 2002, Robbins LLP has gained a prominent reputation for advocating for shareholder rights, helping individuals recoup losses and enhancing corporate governance practices. This latest class action serves as a reminder of the commitment to holding companies accountable for their actions.

Affected stockholders are encouraged to stay informed about the developments in this case. To receive updates about the settlement status or to get alerts regarding any wrongdoing by corporate executives, interested parties should sign up for Stock Watch. This allows for prompt notifications, ensuring shareholders are in the loop about significant events concerning their investments.

If you have any inquiries or require additional details on participating in the class action, you can submit a request via Robbins LLP’s webpage, or you may contact attorney Aaron Dumas, Jr. directly at (800) 350-6003.